https://www.live-feeds.com/feed/world-first-cancer-vaccine-cuts-melanoma-recurrence-or-death-risk-by-42-in-landmark-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/world-first-cancer-vaccine-cuts-melanoma-recurrence-or-death-risk-by-42-in-landmark-trialhttps://www.live-feeds.com/feed/world-first-cancer-vaccine-cuts-melanoma-recurrence-or-death-risk-by-42-in-landmark-trial#u162110Thu, 29 Oct 2026 13:13:05 +0000A personalized mRNA cancer vaccine developed by Moderna and Merck has cut the risk of melanoma recurrence or death by 42 percent when combined with immunotherapy in a landmark clinical trial. The results of the late-stage trial, presented at the European Society for Medical Oncology conference, establish skin cancer as a proving ground for customized genetic immunotherapy. Researchers describe the clinical findings as phenomenal and a triumph of science, marking a major milestone in the development of individualized treatments for oncology patients.Why it mattersThe trial data evaluated the co